Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
14.17
-0.38 (-2.61%)
At close: Jul 31, 2026, 4:00 PM EDT
14.19
+0.02 (0.14%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
1.87B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Iovance Biotherapeutics | 975 |
| Lakefront Biotherapeutics NV | 452 |
| UroGen Pharma | 298 |
| Kardigan | 241 |
| Stoke Therapeutics | 170 |
| Aurinia Pharmaceuticals | 128 |
| Taysha Gene Therapies | 99 |
MESO News
- 4 days ago - Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch - GlobeNewsWire
- 19 days ago - Mesoblast Treats 300 Patients In Phase 3 Low Back Pain Trial For Rexlemestrocel-L - Nasdaq
- 20 days ago - Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 20 days ago - Mesoblast (MESO) Reports Strong Revenue Growth for Ryoncil - GuruFocus
- 20 days ago - Mesoblast (MESO) Sees 6.2% Increase in Share Value - GuruFocus
- 20 days ago - Mesoblast reported Q4 Ryoncil net revenue of $36M - TheFly
- 20 days ago - Mesoblast rises 6.2% - TheFly
- 24 days ago - Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewsWire